Psoriasis: A STAT3-Centric View
AbstractSignal Transducer and Activator of Transcription (STAT)3 has recently emerged as a key player in the development and pathogenesis of psoriasis and psoriatic-like inflammatory conditions. Indeed, STAT3 hyperactivation has been reported in virtually every cell type involved in disease initiation and maintenance, and this factor mediates the signal of most cytokines that are involved in disease pathogenesis, including the central Interleukin (IL)-23/IL-17/IL-22 axis. Despite the recent availability of effective biological agents (monoclonal antibodies) against IL-17 and IL-23, which have radically changed the current standard of disease management, the possibility of targeting either STAT3 itself or, even better, the family of upstream activators Janus kinases (JAK1, 2, 3, and TYK2) offers additional therapeutic options. Due to the oral/topical administration modality of these small molecule drugs, their lower cost, and the reduced risk of eliciting adverse immune responses, these compounds are being actively scrutinized in clinical settings. Here, we summarize the main pathological features of psoriatic conditions that provide the rationale for targeting the JAK/STAT3 axis in disease treatment. View Full-Text
Share & Cite This Article
Calautti, E.; Avalle, L.; Poli, V. Psoriasis: A STAT3-Centric View. Int. J. Mol. Sci. 2018, 19, 171.
Calautti E, Avalle L, Poli V. Psoriasis: A STAT3-Centric View. International Journal of Molecular Sciences. 2018; 19(1):171.Chicago/Turabian Style
Calautti, Enzo; Avalle, Lidia; Poli, Valeria. 2018. "Psoriasis: A STAT3-Centric View." Int. J. Mol. Sci. 19, no. 1: 171.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.